MedTrace Logo

Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1

NCT02129322 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-02-15

No results posted yet for this study

Summary

The study is designed to investigate the effect of adjuvant therapy by Sorafenib, Oxaliplatin and S-1 to prevent the tumor recurrence for hepatocellular carcinoma after liver transplantation

Conditions

Interventions

DRUG

Sorafenib

DRUG

S-1

DRUG

Oxaliplatin

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Weijia fang · First Affiliated Hospital,Zhejiang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-06-30
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02129322 on ClinicalTrials.gov